PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism
Recruiting · NCT07027254 · Interventional (participants receive a specific treatment) · Lead sponsor: Seoul National University Hospital
View the official record on ClinicalTrials.gov →Interventions studied
68Ga-pentixafor PET/CT
What this trial is about
This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET/CT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET/CT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥19 years
- Diagnosed with PA per 2016 Endocrine Society guidelines
- Underwent adrenal CT
- Signed informed consent
Exclusion criteria
- Women who are pregnant, breastfeeding, or may become pregnant
- Individuals who refuse to undergo surgery
- Individuals for whom 68Ga-Pentixafor PET/CT, 11C-Metomidate PET/CT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions
- Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET/CT
- Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy
- Any individual deemed unsuitable for the study at the discretion of the investigator
Where it is running
2 locations listed.
- Samsung Medical Center - Seoul, Gangnam-gu, South Korea
- Seoul National University Hospital - Seoul, Jongno-gu, South Korea